

Inventor: BiaoYang Lin  
Serial No.: 09/729,653  
Filed: December 4, 2000  
Page 2

RECEIVED

SEP 04 2003

TECH CENTER 1600/2900

CURRENT STATUS OF ALL CLAIMS

Claims 1 to 20. (Previously canceled).

21. (Withdrawn) A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:

(a) obtaining a sample from said individual;

(b) measuring a test expression level of PAMP polypeptide by contacting a cell, a cell lysate, or fractionated sample thereof, from said individual with a binding agent selective for PAMP polypeptide residues 1 to 1074 of SEQ ID NO:2, and determining the amount of selective binding of said agent; and

C1 (c) comparing said test expression level of PAMP polypeptide to a control expression level of PAMP polypeptide, wherein a test expression level 2-fold or more greater than said control expression level indicates the presence of a prostate neoplastic condition.

22. (Withdrawn) The method of claim 21, wherein said binding agent selective for said PAMP polypeptide residues 1 to 1074 of SEQ ID NO:2 comprises an antibody.

23. (Withdrawn) The method of claim 22, wherein said binding agent further comprises a detectable label.

24. (Previously canceled).

Inventor: Biaoyang Lin  
Serial No.: 09/729,653  
Filed: December 4, 2000  
Page 3

25. (Withdrawn) A method of diagnosing metastatic prostate cancer in an individual, comprising:

(a) obtaining a sample from said individual, wherein said sample is not a prostate sample;

(b) measuring a test expression level of PAMP polypeptide by contacting a cell, a cell lysate, or fractionated sample thereof, from said individual with a binding agent selective for PAMP polypeptide residues 1 to 1074 of SEQ ID NO:2, and determining the amount of selective binding of said agent;

(c) comparing said test expression level of PAMP polypeptide to a control expression level of PAMP polypeptide, wherein a significant test expression level as compared to said control expression level indicates the presence of metastatic prostate cancer.

CL 26. (Currently amended) ~~A substantially pure~~ An isolated PAMP polypeptide, comprising the amino acid sequence shown as SEQ ID NO: 2 or an amino acid sequence having one or more conservative substitutions relative to SEQ ID NO: 2.

27. (Currently amended) The ~~substantially pure~~ isolated PAMP polypeptide of claim 26, comprising the amino acid sequence shown as SEQ ID NO: 2.

28. (Currently amended) ~~A substantially pure~~ An isolated PAMP polypeptide, comprising an amino acid sequence having at least 90% amino acid identity with at least 350 residues of SEQ ID NO: 2, said 350 residues comprising residues 1075 to 1382 of SEQ ID NO: 2.

Inventor: BiaoYang Lin  
Serial No.: 09/729,653  
Filed: December 4, 2000  
Page 4

29. (Currently amended) The ~~substantially pure~~ isolated  
PAMP polypeptide of claim 28, comprising an amino acid sequence  
having at least 95% amino acid identity with at least 350  
residues of SEQ ID NO: 2, said 350 residues comprising residues  
1075 to 1382 of SEQ ID NO: 2.

---